The FDA has approved a supplemental biologic license application (sBLA) for teplizumab-mzwv (Tzield, Sanofi), expanding its approved age range from 8 years and older down to as young as 1 year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The approval was granted under priority review and makes teplizumab the first disease-modifying therapy available for children in this younger age group.
Wednesday, April 22, 2026
Anthropic’s Mythos Model Is Being Accessed by Unauthorized Users
A small group of unauthorized users have accessed Anthropic PBC’s new Mythos AI model, a technology that the company says is so powerful it can enable dangerous cyberattacks, according to a person familiar with the matter and documentation viewed by Bloomberg News.
A handful of users in a private online forum gained access to Mythos on the same day that Anthropic first announced a plan to release the model to a limited number of companies for testing purposes, said the person, who asked not to be named for fear of reprisal. The group has been using Mythos regularly since then, though not for cybersecurity purposes, said the person, who corroborated the account with screenshots and a live demonstration of the model.
Amneal details $750M Kashiv BioSciences acquisition
Amneal beats Q1 2026 estimates with EPS $0.27 (+29% YoY), revenue $722.5M (+4% YoY), details $750M Kashiv BioSciences acquisition
- Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity plus up to $350M milestone and royalty payments
- Company filed SEC report today disclosing Q1 2026 results and details of the $750M Kashiv acquisition
Boston Scientific beats, but issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41
Boston Scientific beats Q1 2026 estimates with non-GAAP EPS $0.80, revenue $5.203B, issues Q2 EPS guidance $0.82–$0.84, reaffirms 2026 EPS outlook $3.34–$3.41
- GAAP net income reached $1.34B in Q1 2026, approximately doubling compared with the prior-year period.
- Company expects 2026 sales growth of 7.0–8.5% and EPS of $3.34–$3.41.
Elevance raises full-year EPS guidance to $26.75
Elevance Health beats Q1 2026 estimates with adjusted EPS $12.58, revenue $49.49B, raises full-year EPS guidance to $26.75
- Q1 2026 adjusted EPS $12.58, increasing 5% year over year
- Q1 2026 revenue $49.49B, up 1% year over year
- Board declares second-quarter dividend of $1.72 per share
Intuitive Surgical raising 2026 da Vinci procedure outlook
Intuitive Surgical Q1 2026 non-GAAP EPS $2.50 (+38% YoY) on $2.77B revenue, margin expansion, beating estimates and raising 2026 da Vinci procedure outlook
- Revenue grew 23% to $2.77B on 17% procedure growth; recurring revenue comprised 86% of total.
- Non-GAAP operating margin reached 39% and gross margin 67.8%, both improving on operating leverage.
- Q1 2026 net income was $822M, up 23% year over year.
- Placed 431 da Vinci systems (+17%), including 232 da Vinci 5; Ion and SP platforms remained strong.
- Raised 2026 da Vinci procedure growth outlook to 13.5–15.5% from 13–15% previously.
- Company expects 2026 non-GAAP gross margin of 67.5%-68.5%, raising full-year guidance by 50bps despite modest oil and memory headwinds.
- U.S. general surgery, cholecystectomy, appendectomy and benign gynecology robust, while bariatric procedures declined ~10% due to GLP-1s.
- China and Japan underperformed with low tenders, pricing pressure and capital constraints driving below-average procedure growth.
- Innovation-led revenue growth outpaced procedures via da Vinci 5 pricing, SP stapler adoption and expanding digital capabilities.
TD Bank Mulls Hedging Data Center Debt With Rare SRT Deal
Toronto-Dominion Bank is weighing a rare type of significant risk transfer to hedge current and future data center exposure as tech companies ramp up artificial intelligence investment.
The initial size of the reference portfolio is around $1 billion, according to people familiar with the matter. The potential transaction would include a forward-flow arrangement, which allows the bank to increase the size of the SRT over time, said the people, who asked not to be identified because the matter is private.
Subscribe to:
Comments (Atom)